×

RestorGenex to Present at the Future Leaders in the Biotech Industry Conference

BUFFALO GROVE, Ill., March 18, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present at the 22nd Annual Future Leaders in the Biotech Industry Conference, being held Friday, March 20, 2015, in New York, NY. Mr. Simes will provide a corporate overview at 9:00am ET. The presentation will be webcast and available at https://www.webcaster4.com/Webcast/Page/818/7620.

About RestorGenex Corporation

RestorGenex is a specialty biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the ophthalmologic, oncologic and dermatologic space. RestorGenex's lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. The current pipeline also includes a "soft" anti-androgen compound for the treatment of acne vulgaris. RestorGenex's novel inhibition of the PI3K pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating safe and effective treatments and innovative therapies. For additional information please see: www.restorgenex.com.

About the Future Leaders in the Biotech Industry Conference

Future Leaders connects leading portfolio managers, bankers and analysts with investor-validated, milestone-rich private and public companies in key therapeutic areas, offering new investment and partnering opportunities and the chance to find companies with tier-jumping potential. Last year, more than 500 delegates congregated at Future Leaders, representing top financial institutions, pharmaceutical business development executives, and high net worth investors active in the sector. Last year's Future Leaders audience controlled more than $650 billion in equity assets.

CONTACT: The Trout Group LLC Marcy Nanus, 646-378-2927 mnanus@troutgroup.com

Source:RestorGenex